Rankings / Comparisons

Metformin vs Acarbose

Two glucose-control drugs that have surfaced in longevity research; different mechanisms and side-effect profiles.

Reviewed by Read Off Label · How we grade

Score comparison

Metformin has the higher descriptive composite (B+, 7.2/10) compared with Acarbose (B-, 6.3/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

Metformin

B+ 7.2/10

aka Glucophage, Glumetza, Fortamet, Riomet

Evidence
Strong (in T2D); Moderate observationally (non-diabetics); Preclinical (pure anti-aging) (8/10)
Benefit
Varies (5/10)
Risk
Low-Med (GI side effects; B12 deficiency with chronic use; lactic acidosis rare; may blunt exercise adaptations) (7/10 safety)
Legality
Rx (off-label for longevity)
Dose / route context
500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals
Class
Prescription
Last reviewed
Jul 1, 2026

Read Off Label grades Metformin as B+ (7.2/10) based on strong evidence, variable benefit magnitude, and a low-med-risk safety profile.

UKPDS showed 36% reduction in all-cause mortality in T2D.

Studied, labeled, or reported-use context: 500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals — Rx; not individualized guidance.

What it is

UKPDS showed 36% reduction in all-cause mortality in T2D. TAME trial ($75M, 3000 non-diabetic older adults) repeatedly delayed — FDA approved design but unfunded. 2019 Konopka data: may blunt exercise-induced mitochondrial adaptations.

Mechanism

Complex I mild inhibition → AMPK activation → mTOR inhibition; improved insulin sensitivity; possible gut microbiome effects; reduced hepatic gluconeogenesis

Full Metformin review →

Acarbose

B- 6.3/10

aka Precose, Glucobay

Evidence
Moderate (human glycemic control); Strong (rodent lifespan especially in males) (6/10)
Benefit
Med (Varies by gender) (5/10)
Risk
Low-Med (GI flatulence is common) (7/10 safety)
Legality
Rx (T2D); often OTC outside US
Dose / route context
25-100 mg TID with first bite of meals
Class
Prescription
Last reviewed
Jun 8, 2026

Read Off Label grades Acarbose as B- (6.3/10) based on moderate evidence, med benefit magnitude, and a low-med-risk safety profile.

ITP: extended male mouse lifespan by 22%, female by 5% — one of the most robust ITP findings.

Studied, labeled, or reported-use context: 25-100 mg TID with first bite of meals — Rx (T2D); often OTC outside US; not individualized guidance.

What it is

ITP: extended male mouse lifespan by 22%, female by 5% — one of the most robust ITP findings. Human longevity data is extrapolated from diabetes trials and Japanese cohort data. Cheap and well-tolerated if GI side effects are acceptable.

Mechanism

Inhibits intestinal alpha-glucosidases; slows carbohydrate digestion; blunts postprandial glucose spike; produces more favorable microbiome (SCFA production)

Full Acarbose review →

Common questions

How do the evidence profiles of Metformin and Acarbose compare?
Metformin has the higher descriptive composite (B+, 7.2/10) compared with Acarbose (B-, 6.3/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between Metformin and Acarbose?
Two glucose-control drugs that have surfaced in longevity research; different mechanisms and side-effect profiles.
Can you take Metformin and Acarbose together?
The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.